Diagnosed and Not Treated: How Prostate Active Surveillance Works
You get the biopsy result and the word cancer is on it. Then the urologist says the plan is to not treat it, just watch it. For most men that sounds like two sentences that cannot both be true. They can. For low-risk prostate cancer, active surveillance is the preferred plan in US urology guidelines, and the long-term data behind it is some of the strongest in oncology. What makes it safe is not the diagnosis. It is the watching, and the watching only works if every PSA, every MRI and every biopsy is read against the ones before it.
This post walks through what active surveillance is, what Gleason 6 means, what the tests look like, what the big trials found, and what moves a man from watching to treating.

Why "cancer, but no treatment" is a real plan
Many prostate cancers found through a PSA test are small, low grade and slow. Treating all of them would expose many men to side effects for cancers that might never have harmed them. The American Cancer Society lists urinary incontinence and erectile dysfunction as the two major possible side effects of radical prostatectomy.
Active surveillance separates those cancers over time. The American Cancer Society defines it as monitoring the cancer closely, with a plan to treat it if it shows signs of growing faster. Watchful waiting, or observation, is a less intensive follow-up that relies more on symptoms. The words get used loosely, so ask which one your plan is.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
The AUA/ASTRO guideline on clinically localized prostate cancer (2022, amended 2026) tells clinicians to recommend active surveillance as the preferred management option for low-risk prostate cancer, as a strong recommendation backed by the highest grade of evidence.
What Gleason 6 and Grade Group 1 actually mean
The grade is the most important number on the biopsy report for this decision. A pathologist scores the two most common patterns in the tissue from 3 to 5 and adds them into the Gleason score. Reports now also give a Grade Group from 1 to 5.
Per the American Cancer Society:
- Grade Group 1 is a Gleason score of 6 or less.
- Grade Group 2 is Gleason 3+4=7.
- Grade Group 3 is Gleason 4+3=7.
The ACS also notes that scores below 6 are rarely used in practice, which is why Gleason 6 is effectively the bottom of the scale, not the middle. Cancer Research UK describes Grade Group 1 cells as looking similar to normal prostate cells and likely to grow very slowly, if at all.
Order matters at the 7 line. A 3+4 and a 4+3 both add up to 7, but the first is mostly pattern 3 and the second is mostly pattern 4, which is why they land in different Grade Groups. Grade Group 2 sits in a gray zone where surveillance is discussed for some men and treatment for others. If you want the difference between grade (how aggressive the cells look) and stage (how far the cancer has spread), our explainer on tumor grade versus stage walks through both.
Who active surveillance fits
Grade is not the only input. The American Cancer Society describes the low-risk group as a cancer that has not grown outside the prostate, is Grade Group 1, has a PSA level under 10, and is clinical stage cT1 to cT2a, meaning small or not felt on exam. The ACS adds that surveillance and observation are generally options when the cancer is not causing symptoms, is small and limited to the prostate, and is expected to grow slowly based on its risk group or a molecular test.
Some men in the next tier up qualify too. For favorable intermediate-risk prostate cancer, the AUA/ASTRO guideline says clinicians should discuss active surveillance, radiation therapy and radical prostatectomy, which puts surveillance on the table for selected Grade Group 2 cancers rather than ruling it out.
When the picture is borderline, molecular tests such as Decipher, Oncotype DX Prostate and Prolaris measure gene activity in the cancer cells and return a score where higher means more likely to grow or spread (American Cancer Society). They add to the grade, PSA and MRI; they do not replace them.
What the watching looks like, year by year
Active surveillance is not a single test. It is a schedule. The American Cancer Society describes a typical one:
- PSA blood test about every 3 to 6 months.
- Digital rectal exam about once a year.
- Prostate biopsies and imaging every 1 to 3 years.
- Multiparametric MRI, which can sometimes reduce how often biopsies are needed.
Programs differ, and the ACS notes schedules can be adjusted to the person.
MRI has changed the routine, but it has not replaced the needle. The AUA/ASTRO guideline says men on surveillance should be monitored with serial PSA values and repeat biopsies, and that MRI should be used to sharpen the risk picture but should not replace periodic biopsy. Reading the MRI report itself is its own skill; our guide to PI-RADS and the prostate MRI report explains what the 1 to 5 score means and when a lesion earns a targeted biopsy.
The weak point is not the schedule. It is that each result lives somewhere different: the PSA in a lab portal, the MRI in a radiology system, the biopsy at a pathology lab. Five years in, the decision depends on how a dozen results line up.
What the long-term data shows
Two bodies of evidence carry most of the weight.
The ProtecT trial. In the United Kingdom, 1,643 men aged 50 to 69 with PSA-detected localized prostate cancer were randomly assigned to active monitoring (545 men), prostatectomy (553) or radiotherapy (545), and followed for a median of 15 years (Hamdy and colleagues, New England Journal of Medicine, 2023). Death from prostate cancer was 3.1% with monitoring, 2.2% with surgery and 2.9% with radiotherapy, with no significant difference between groups. Death from any cause was similar in all three.
The trade-off showed up elsewhere. Metastases developed in 9.4% of the monitoring group, against 4.7% after surgery and 5.0% after radiotherapy. Clinical progression was also higher with monitoring. And 24.4% of the monitoring group were alive at the end of follow-up without ever having had prostate cancer treatment. The authors concluded that prostate cancer mortality was low regardless of the treatment assigned, so the choice involves weighing the benefits and harms of each.
Two caveats. More than a third of the men had intermediate or high-risk disease at diagnosis. And commentators note its monitoring was less intensive than modern surveillance, which uses MRI and genomic tests more routinely.
The Johns Hopkins cohort. Among 1,818 men with Grade Group 1 cancer on surveillance, the cumulative risk of prostate cancer death or metastasis was 0.1% at both 10 and 15 years (Tosoian and colleagues, European Urology, 2020). The authors note their selection and monitoring are more stringent than many other programs, and that outcomes may differ with less intensive follow-up. That last line is the real message: the safety of surveillance depends on the surveillance.
What moves a man from watching to treating
Surveillance is built to end in treatment for some men, and that is the plan working, not failing. In the Hopkins cohort, 48% of men had switched to treatment ten years after enrolling, per the study's patient summary. In ProtecT, about 61% of men first assigned to monitoring had received radical treatment by 15 years, according to a published commentary on the trial.
The American Cancer Society puts the trigger simply: treatment is considered when tests show the cancer is starting to grow faster. In practice, the change most programs track is on the biopsy. In the Hopkins cohort, the cumulative chance of a biopsy grade reclassification, meaning a later biopsy showed a higher grade than the first, was 21% at 5 years, 30% at 10 years and 32% at 15 years. Men who had an MRI-targeted biopsy before enrolling were less likely to be reclassified later, which suggests some "upgrades" are cancers that were under-sampled the first time.
None of these triggers is a single number. A higher grade means comparing two biopsies, a faster-growing cancer means comparing PSA values across months, a new lesion means comparing two MRIs. The question is not "what is my PSA" but "what is my PSA doing".
How Healz reads a surveillance file across the years
This is where an AI second opinion earns its keep. Active surveillance is a trend problem, and trends get lost between portals and hospitals. Healz has memory built for exactly this. It pulls the medical facts out of every report you upload, dates them, keeps abnormal values up front and connects them across months and years of the case. So your PSA line, your PI-RADS scores and your Grade Groups sit in one timeline, and a change shows up as a change.
Healz is Cancer-Trained AI. It reads the pathology report, the MRI report and the lab results together, so a rising PSA is read against the MRI and the last biopsy grade, not in isolation. Its root-cause technology asks the questions a rushed visit skips: was the first biopsy MRI-targeted, how many cores held cancer, is a confirmatory biopsy due. It searches the latest studies and trials for your risk level.
Everything sits in one chat, not ten apps, in a library that is private to you, encrypted, never used for ads. Before each check-in, Healz can create a ready PDF of questions for your urologist, built from your own numbers. And when a result changes and you want a human view, you can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- What is active surveillance for prostate cancer?
It is close monitoring of a low-risk prostate cancer with a plan to treat it if it shows signs of growing faster, per the American Cancer Society. It usually involves PSA tests every 3 to 6 months, a yearly rectal exam, and biopsies and imaging every 1 to 3 years. The AUA/ASTRO guideline (amended 2026) names it the preferred option for low-risk prostate cancer.
- Is Gleason 6 prostate cancer dangerous?
Gleason 6 is Grade Group 1, the lowest grade used in practice, and Cancer Research UK describes it as likely to grow very slowly, if at all. In the Johns Hopkins surveillance cohort of 1,818 men with Grade Group 1 cancer, the risk of prostate cancer death or metastasis was 0.1% at 15 years (European Urology, 2020). It still needs monitoring, because a later biopsy can find a higher grade.
- Is active surveillance as safe as surgery or radiation?
In the ProtecT trial, 15-year prostate cancer death was 3.1% with monitoring, 2.2% with surgery and 2.9% with radiotherapy, with no significant difference (NEJM, 2023). Metastases were about twice as common with monitoring, 9.4% against roughly 5%. Many men on monitoring also avoided treatment side effects, which is the trade-off the trial's authors say each man has to weigh.
- What is the difference between active surveillance and watchful waiting?
Active surveillance follows the cancer closely with regular PSA tests, exams, MRI and biopsies, with the intent to treat for cure if it changes. Watchful waiting, or observation, is less intensive and relies more on symptoms, and it is often used for older men or men with other serious health conditions (American Cancer Society). Ask which one your plan is, because the follow-up is very different.
Diagnosed and not treated is not neglect. For low-risk prostate cancer it is the standard of care, backed by fifteen years of data. What keeps it safe is the watching: every PSA, MRI and biopsy read against the ones before it.
Written by Healz Team · Filed under Health Insights